Binimetinib

BRAF V600 Mutation

UNICANCERSmall moleculePhase 2Active

BB

64/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 49/ 100
Competitive Position: 89/ 100

Competitive context

19 Active assets in the BRAF V600 Mutation cohort.

Asset / Sponsor	Phase	Rating
Encorafenib UNICANCER	Phase 2	B
Nivolumab H. Lee Moffitt Cancer Center and Research Institute	Phase 2	B
gsk1120212 Xynomic Pharmaceuticals, Inc.	Phase 2	B
Cobimetinib ABM Therapeutics Corporation	Phase 2	B
Carboplatin Guangdong Provincial People's Hospital	Phase 2	CCC

View all 21 →

Same molecule, other indications

Binimetinib is also rated in:

metastatic malignant neoplasm in the colonDormant

BB

Indicative ·

70 / 100

cutaneous melanomaDormant

BB

Indicative ·

68 / 100

triple-negative breast carcinomaDormant

BB

Indicative ·

66 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.